Dr. Toni Choueiri of the Dana Farber Cancer Institute discusses CheckMate 025 phase III trial: Outcomes by key baseline factors and prior therapy for nivolumab versus everolimus in advanced renal cell carcinoma.
Advertisement Single Below Content
Advertisement Single Below Content
Advertisement Single Below Content